October 5, 2017
Depression, bipolar disorder, ADHD, schizophrenia and obsessive compulsive disorder – mental illness takes multiple forms.
September 1, 2017
Vacation season? Perhaps. But summer hasn’t slowed the Institute for Patient Access’ steady stream of physician-led insight on policy issues that matter to patients and their health care providers.
August 1, 2017
People are living longer, healthier lives today with the help of advanced medicine. But innovative drugs can be expensive. Insurance…
July 28, 2017
Most all of us know someone living in a long-term care facility – a friend, a former neighbor, a family member. But not all may be aware of a recent debate about the use of a certain type of medication – antipsychotic medication – for seniors living in these facilities.
July 6, 2017
Long-awaited treatment for a movement disorder known as tardive dyskinesia could remain out of reach – unless an upcoming cost-effectiveness analysis acknowledges its value to patients.
June 29, 2017
Some wore shades, others “showed purple.” But advocates across the board used June’s Migraine & Headache Awareness Month to draw attention to a condition whose patients face debilitating symptoms and far too few treatment options.
June 20, 2017
In Massachusetts, some patients with epilepsy must try and fail on their health plans’ preferred prescription medications not once, not twice, but three times before getting the treatment their doctor originally prescribed.
June 6, 2017
For chronic migraine patients, the only thing better than making a headache stop is preventing it altogether. And new research suggests that patients may soon have new options for doing just that.
February 28, 2017
Rare Disease Day brings international attention to the plight of patients who struggle with ALS, Gaucher disease, cystic fibrosis and other less common conditions. This year’s theme is research, a challenge for any disease state but especially for conditions with small patient populations.
February 7, 2017
Chronic migraine is seldom a lone condition, explains a new white paper from the Headache & Migraine Policy Forum.
